Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown.
INTRODUCTION
The outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings have never been directly compared. Conventional wisdom suggests that major depression presenting to primary care is a less severe [1] [2] [3] and less chronic illness. 1, 4, 5 However, more recent data suggest that newly treated depressions presenting to both settings are similar. 6 The only direct comparison concerning depressive illness in which patients presenting to both settings met identical eligibility criteria found that baseline patient characteristics, including depressive severity 7 and current psychiatric comorbidity, 8 were indistinguishable between settings.
Treatment guidelines suggest that patients with depression who present to primary care clinicians should be treated initially by them, unless suicidality or bipolarity is present, or 1 or 2 treatments have failed in the current episode. [9] [10] [11] These recommendations, based primarily on clinical consensus, imply that most patients with depression presenting to primary care have a similar likelihood of response as those seen in specialty settings. These recommendations assume that adequate care is being provided in both specialty and primary care settings. However, the recently completed National Comorbidity Survey Replication reported that for patients identified as depressed and requiring treatment, only 41.9% (95% CI, 35.9-47.9) received adequate treatment (defined as 4 outpatient visits and 30 days of antidepressant therapy, or 8 psychotherapy sessions). 12 Of those who receive depression treatment, 64% (95% CI 55.4-73.1%) of those seen in SC settings and 41% (95% CI 31.3-57.2%) of those seen in general medical settings received adequate care. Using a nationally representative sample of adults who were initiating a new episode of antidepressant treatment, Olfson and colleagues found that 42.4% discontinued their medication during the first month of treatment. 13 The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a broadly inclusive effectiveness trial that enrolled self-declared depressed outpatients from primary and specialty care settings using identical enrollment criteria. Our earlier analyses confirmed that depressive severity was not different, and symptomatic presentations did not differ substantially between the 2 settings at baseline. 7, 8 . Whether representative patients who are treated with similar levels of adequate care have different outcomes in primary vs psychiatric care settings has never been directly evaluated. The data from STAR*D enabled us to determine whether the outcomes of patients who present with equivalent degrees of depression severity and are treated with equivalent high-quality measurement-based care differ by whether they presented to a primary or specialty setting.
This report addresses the following as""/because"" questions: (1) Did the treatment delivered in the 2 settings differ? (2) Did the symptomatic outcomes differ as a function of whether participants were treated in primary or specialty settings?
METHODS

Design Overview and Setting
The rationale and design of STAR*D are detailed elsewhere. [14] [15] [16] Briefly, the purpose was to define prospectively which of several treatments are most effective for outpatients with nonpsychotic depression who had an unsatisfactory clinical outcome to an initial and, if necessary, subsequent treatment(s). STAR*D participants were enrolled at 18 primary and 23 specialty (psychiatric) settings across the United States. Both primary and specialty care sites that provided care to public and private sector patients were selected on the basis of having (a) sufficient patient numbers, (b) sufficient numbers of clinicians, (c) sufficient administrative support, and (d) sufficient numbers of racial/ethnic minority subjects so that the study population could mirror the U.S. Census and results would be widely generalizable. The median number of clinicians at the 18 primary care sites was 14.5 compared to 12.0 at the 23 specialty sites. Three quarters of the facilities were privately owned, and approximately 2 thirds were freestanding (i.e., not hospital- . Advertising for symptomatic volunteers was proscribed. Broadly inclusive selection criteria were used. 14, 16 Patients with a baseline score ≥14 (moderate severity) on the CRC-rated 17-item Hamilton Rating Scale for Depression (Hamilton) 17,18 were eligible. This level of severity (a) indicates a clear need for treatment; (b) reflects a level of depression for which medication is superior to placebo 19, 20 ; (c) approximates the level of depressive severity seen in major depressive episodes in these settings 6, 21 ; and (d) is similar to the Hamilton eligibility criteria used in prior primary care clinical trials of major depression. [22] [23] [24] Patients who were pregnant, intending to become pregnant, or breastfeeding were excluded. Patients were excluded if they had a bipolar, psychotic, obsessive compulsive, or eating disorder; a substance abuse/dependence requiring inpatient treatment; a seizure disorder or other general medical condition that contraindicated medications used in the first 2 protocol treatment steps; or a clear history of nonresponse or intolerance (in the current major depressive episode) to any protocol treatment in the first 2 treatment steps. All other psychiatric and medical comorbidities were allowed. Risks and benefits associated with STAR*D participation were explained to participants, who provided written informed consent before study entry. The protocol was approved and monitored by institutional review boards at the National Coordinating Center (Dallas), the Data Coordinating Center (Pittsburgh), each relevant Clinical Site and Regional Center, and the Data Safety and Monitoring Board of the National Institute of Mental Health (NIMH; Bethesda, MD, USA).
Baseline Measures
At baseline, the CRCs collected standard demographic information, self-reported psychiatric history, and current medical conditions as evaluated by the Cumulative Illness Rating Scale (CIRS; a higher score indicates greater medical comorbidity). 25 The CRCs also assessed depressive symptom severity using the 16-item Quick Inventory of Depressive SymptomatologyClinician-rated (QIDS-C 16 ). Participants completed the QIDS Self-Report (QIDS-SR 16 ) [26] [27] [28] (secondary outcomes).
Participants completed the Psychiatric Diagnostic Screening Questionnaire (PDSQ) 29, 30 to estimate the presence/absence of 11 potential concurrent DSM-IV disorders. Based on prior reports, 29 we selected a scoring procedure and thresholds that yielded a 90% specificity in relation to the gold standard diagnosis rendered by a structured interview (the Structured Clinical Interview for DSM-IV, or SCID 31 ).
ROAs, blinded to treatment characteristics and clinical site, used a structured telephone interview 32 at baseline to collect the Hamilton (primary outcome measure) and the 30-item Inventory of Depressive Symptomatology-Clinician-rated (IDS-C 30 ). 26, 33 Responses to items on these measures were used to estimate the presence of atypical, 34 anxious, 35 
Course of Treatment Measures
An integral part of our measurement-based care intervention (see below) was the collection at each visit of clinically relevant information to inform medication decision making. At each visit, QIDS-SR 16 (primary outcome) and QIDS-C 16 ratings were obtained and participants reported side effects using three 7-point scales that evaluated frequency, intensity, and global burden measures, respectively.
14
Intervention
As detailed elsewhere, 40 citalopram was selected as a representative selective serotonin reuptake inhibitor given the relative absence of discontinuation symptoms, demonstrated safety in elderly and medically fragile patients, once-a-day dosing, few dose adjustment steps, and favorable drug-drug interaction profile. 14, 16 The aim of the treatment was to achieve symptom remission (QIDS-C 16 score ≤5). The protocol 14, 16 required a fully adequate dose for a sufficient time to maximize the likelihood of achieving remission and ensure that participants who did not reach remission were truly experiencing inadequate benefit from the medication. The treating clinician in each respective setting, whether primary or specialty care, made all antidepressant prescription decisions with guidance by the treatment protocol. The protocol aimed to provide an optimal dose of citalopram based on dosing recommendations in a treatment manual (www.star-d.org). Citalopram was to be started at 20 mg/day and then raised to 40 mg/day by week 4 and to 60 mg/day (final dose) by day 42 (week 6). Appropriate flexibility was allowed (citalopram started at <20 mg/day, slower dose escalation) to minimize side effects; maximize safety; optimize the chances of therapeutic benefit; and enable patients with concomitant medical conditions, substance abuse/dependence, other psychiatric disorders, or sensitivity to medication side effects to be included safely in the sample.
The protocol recommended treatment visits at 2, 4, 6, 9, and 12 weeks (with an optional week 14 visit if needed). After an optimal trial (based on dose and duration), remitters and responders could enter the 12-month naturalistic follow-up; however, all non-remitters were encouraged to enter the subsequent randomized trial (Level 2 of STAR*D). Participants could discontinue citalopram before 12 weeks if: 1) intolerable side effects required a medication change, 2) an optimal dose increase was not possible owing to side effects or participant choice, or 3) Figure 1 . Consort Chart Hamilton: 17-item Hamilton Rating Scale for Depression. significant symptoms (QIDS-C 16 score ≥9) were present after 9 weeks at maximally tolerated doses. A web-based treatment monitoring system provided feedback to CRCs regarding individual participant fidelity to the treatment recommendations, enabling CRCs to guide physicians in vigorously dosing the medication when inadequate symptom reduction occurred despite acceptable side effects. These elements of the protocol represented an intensive effort to provide consistent, high-quality care. 41 The ultimate antidepressant dosing decision, however, was made by the treating clinician.
Safety Assessments
In addition to side effects, serious adverse events were monitored with a multitiered approach that involved the CRCs, study clinicians, the interactive voice response system, the clinical manager, safety officers, regional center directors 42 , and the NIMH Data Safety and Monitoring Board. Intolerance was defined a priori as either leaving treatment before 4 weeks for any reason, or leaving at or after 4 weeks because of intolerance.
Concomitant Medications and Psychotherapy
Concomitant treatments for current medical conditions (as part of ongoing clinical care), for associated symptoms of depression (e.g., sleep, anxiety, and agitation), and for citalopram side effects (e.g., sexual dysfunction) were permitted based on clinical judgment. Stimulants, anticonvulsants, antipsychotics, alprazolam, nonprotocol antidepressants (except trazodone ≤200 mg at bedtime for insomnia) were prohibited. Also, concomitant evidence-based psychotherapies, such as cognitive-behavioral psychotherapy or interpersonal psychotherapy, were forbidden. Non evidence-based psychotherapy, such as supportive psychotherapy, was allowed.
Outcomes
Our primary outcome was remission, defined as an exit Hamilton score ≤7 (or last observed QIDS-SR 16 score ≤5). As defined by the original proposal, participants for whom the exit Hamilton score was missing were designated as not achieving remission. Our secondary outcome was response, defined as a reduction of ≥50% in baseline QIDS-SR 16 at the last assessment.
Statistical Analysis
Summary statistics are presented as means and standard deviations for continuous variables, and percentages for discrete variables. Student's t tests and Mann-Whitney U tests were used to compare continuous baseline clinical and demographic features, treatment features, and side effect and serious adverse event rates across setting. Chi-square tests compared discrete characteristics across setting.
Logistic regression models were used to compare remission and response rates, after adjusting for the effect of baseline characteristics that were not equally distributed across setting and Regional Center. Times of first remission and first response were defined as the first observed point using clinic visit data. Log-rank tests were used to compare the cumulative proportion of participants with remission or response across settings. Kaplan-Meier curves were used to display cumulative proportion of first remission and first response by treatment setting. Additional exploratory logistic regression analyses were conducted to determine whether there was a differential effect of setting on remission based on the QIDS-SR 16 at exit by the baseline severity of depression.
Statistical significance was defined as a 2-sided p value less than 0.05. No adjustments were made for multiple comparisons, so results must be interpreted accordingly.
RESULTS
Sample Description/General
Most potential participants approached for the study were both eligible and enrolled (see Fig. 1 ). The study enrolled 4,041 eligible participants, 39% (n=1,575) from primary and 61% (n=2,466) from specialty care. The percentages of participants with a Hamilton <14 (15% PC and 15% SC), with a missing baseline Hamilton (9% PC vs 7% SC), and without a postbaseline measure (8% PC vs 7% SC) did not differ by setting. The evaluable sample of 2,876 consisted of 1,091 participants in primary care and 1,785 participants in specialty care (38% and 62% of the final sample, respectively 40 ).
Sociodemographic and Clinical Features at Baseline
Primary care participants were older; were more likely to be female, have public insurance (Medicaid/Medicare), and African American; were substantially more likely to be Hispanic; and less likely to have completed college (Tables 1 and 2) . Clinical features and course of depression were essentially indistinguishable between primary and specialty care participants. Presenting depressive severities were identical (Hamilton=21.8 in both PC and SC). The spectrum of depressive severity and the presence of current psychiatric comorbidities did not substantially differ between settings. Roughly half of the participants in each setting had an anxiety disorder. Primary care participants were less likely to have recurrent depression (≥2 episodes) and to have their first episode before age 18, and slightly less likely to present with melancholic features. Fewer primary care participants reported a prior suicide attempt (14.1% vs 20.3%, p<0.001). Primary care participants were more likely to have a chronic depression (current episode ≥24months) and to present with anxious features.
Primary care participants had more current medical comorbidity. Of the 13 medical conditions identified (indicated by CIRS score ≥2, at least moderate disability), 11 were significantly more prevalent in primary care. Primary care participants had better mental health functioning and social adjustment scores, whereas specialty participants had better physical functioning and quality of life scores, although the magnitude of these differences was small.
Treatment Characteristics by Clinical Setting
Treatment provided differed only minimally by setting (Tables 3  and 4 ). The number of actual visits was slightly lower in primary care (4.7 PC vs 4.9 SC, p=.005), but time to first treatment visit, time in treatment (mean of approximately 10 weeks), and time from final dose to study exit did not differ. Mean doses at Level 1 exit in primary settings (40.6 mg/day, SD=16.6) were slightly lower than those in specialty settings (42.5mg/day, SD=16.8, p=.003), although this is unlikely to be clinically meaningful. The variable most clearly distinguishing of the 2 settings was the greater tendency of psychiatric clinicians to prescribe higher doses of citalopram; smaller proportions of primary care participants received a dose of ≥50 mg during treatment (39.4%, vs 46.1%, p<.001) and were receiving ≥50 mg at study exit (34.8% vs 41.8%, p<.001). Still, in both settings, the most commonly prescribed dose range participants received at some point during the study, and at study exit, was ≥50 mg.
Despite the slightly higher prescribed doses of citalopram in specialty settings, we found no difference in side-effect burden (Table 5 Table 6 ).
Mean depressive symptom severity at exit was virtually identical between settings (QIDS-SR 16 : 9.2 PC vs 9.1 SC, p=.63), and the mean change in depressive severity did not differ by clinical setting (Table 7) . Adjusting for baseline differences produced a slightly lower mean depressive severity at exit in GMC general medical condition, SE side effect, SAE serious adverse event primary care settings, although the difference is unlikely to be clinically meaningful. The time to the first indication of remission ( Fig. 2 ) and response (data not shown) did not differ by setting (remission; p=.12, response; p=.97). For those who reached remission or response, the mean times to remission and response were 6.2 weeks primary vs 6.9 weeks specialty, and 5.5 weeks primary vs 5.4 weeks specialty, respectively. The percent remitting at each week did not differ by setting, with remission in each setting most likely to occur 6 weeks after the start of treatment.
Association of Baseline Severity and Probability of Remission by Clinical Setting
As expected, baseline depressive severity had an effect on outcome. In both settings, higher baseline depressive severity was associated with a lower likelihood of remission (Hamilton: OR=0.76, p=.005 in PC; OR=0.80, p<.001 in SC for a five-unit increase in the Hamilton score) (QIDS-SR 16 : OR=0.60, p<.001 in PC; OR=0.77, p=.004 in SC for a 5-unit increase in the QIDS-SR 16 score). Interestingly, after controlling for baseline and treatment differences, a differential effect (p=.006) on remission based on the QIDS-SR 16 was detected-results with Hamilton and QIDS-SR 16 were identical and we report only on the latter, for which a recorded outcome score was more likely (Fig. 3) .
Specifically, comparing remission rates in specialty vs primary care participants with baseline QIDS-SR 16 scores of 11.2, 16.2 (mean baseline score), and 21.2 gives the odds ratios of 0.626, 0.903, and 1.304, respectively. These higher odds ratios with higher baseline QIDS-SR 16 scores indicate that as the severity of depression increases, the odds of remission increase in specialty care relative to the odds of remission in primary care.
DISCUSSION
To our knowledge, this study is the first to directly compare symptomatic outcomes in a highly representative outpatient sample with nonpsychotic depression treated in primary vs specialty care settings. Given the broadly inclusive selection criteria, these results should apply to routine clinical practice in both settings if similar high-quality care procedures are implemented.
The scheduling of clinic visits was consistent with evidencebased treatment guidelines, 9, 11, 43 FDA recommendations, 44, 45 and APA guidelines. 43 The mean dose of citalopram was higher than both the dose most commonly prescribed in clinical trials (20 mg per day) 46 and the average U.S. dose reported from a large managed care database (24 mg/day). 47 The mean dose at Level 1 exit did not differ between settings in a clinically results found in earlier studies. [6] [7] [8] Our findings suggest that clinicians would be well advised to prepare for patients with a similar range of depression severity and psychiatric comorbidity regardless of setting. Overall, the likelihood of a clinically relevant benefit (i.e., remission, response) and the speed with which response or remission was reached did not differ across settings. This indicates that equivalent treatment provided across settings will likely produce generally equivalent outcomes.
Consistent with prior studies in both settings, [48] [49] [50] [51] [52] greater baseline depressive severity was associated with a lower likelihood of remission in each setting. The likelihood of improvement for participants with milder initial severity appeared greater in primary care. As initial depressive severity increased, the differences between the 2 settings decreased until, at approximately QIDS-SR 16 ≥16 (moderate-to-severe depression, 27 equivalent to Hamilton ≥20 28 ), the likelihood of remission became greater in specialty care participants. Why might clinical setting be an effect modifier? The effect cannot be explained by measured baseline demographics, psychiatric and medical comorbidities, or depression care provided, as our analysis controlled for these factors. Possible explanations involve patient and physician/clinic factors not measured in our study. For example, primary care clinicians may have been better able to manage comorbid medical conditions associated with milder depressive severity, leading to better psychiatric outcomes. Similarly, psychiatric clinicians may have been better able to manage associated comorbid psychiatric symptoms, substance use difficulties, or medication-related side effects. Indeed, psychiatric clinicians were more likely to concomitantly prescribe anxiolytics (11.7% vs 5.9%, p<.001), sedatives (16.1% vs 10.2%, p<.001), and trazodone (17.5% vs 11.9 %, p<.001), although they did not differ in the likelihood of prescribing Viagra (2.9% vs 3.9%, p= 0.17). Also, participants at specialty sites likely had greater access to the non-depression-specific therapies (e.g., psychodynamic or supportive therapy) permitted by our protocol; however, we did not record such information.
What do these data mean for management of depression in real world primary and specialty care clinics? Patients with at least a moderate severity of depression improved in both settings, but primary care patients with more severe depressive symptoms might benefit from closer monitoring, and earlier consideration of referral or more vigorous dosing. These results highlight the import of using a chronic disease approach to enhance outcomes, consisting of a collaborative definition of problems, targeting and goal setting, and active and sustained follow-up with contact at specified intervals [53] [54] [55] [56] [57] [58] .
The main findings-that the 2 settings delivered a comparable level of high-quality depression care and equivalent outcomes-occurred within the context of a measurementbased care approach. This systematic approach to treatment is designed to be easily implemented in busy primary care or psychiatric practices. 59 The routine measurement of symptoms and side effects using easily administered tools, with guidance at critical decision points regarding when and how to modify the medication doses, provides a flexible treatment approach to ensure the delivery of an adequate dose and duration of the antidepressant medication(s) and makes it easier for clinicians to use a decision support system. 60 As with prior approaches, 22, [61] [62] [63] [64] [65] [66] the use of staff to closely monitor response and manage care in each setting is a key component of measurement-based care. However, measurement-based care further involves the use of critical decision points, which are scheduled times during treatment when the algorithm prompts clinicians to actively decide on a management change based on time on medication, total depressive severity score, and toleration of side effects. The algorithm applied in this study reflects depressive severity scores assessed by the depression specialist (QIDS-C 16 ); however, the QIDS-SR 16 can substitute 28 , making use of this approach even easier. These key features-having support staff collect easily administered depressive severity and side effects measures at follow-up, providing this feedback to treating clinicians whose management plan is guided by a flexible medication algorithm-have proven feasible in other busy real world primary care settings. 67 Study limitations include the absence of randomization to primary or specialty clinics, meaning unknown patient factors 
CONCLUSION
We have provided the first direct comparison of outcomes for patients presenting with identical severity of major depressive disorder in primary and specialty care settings that provide identical care. Our data suggest that identical remission and response rates can be achieved in both settings when identical care is provided. These data are the first to provide an evidence base on which to develop subsequent guidance for management in one or the other setting, and they underscore the importance of diligently managing depression in these settings.
